Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more) Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more) Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News VIVESTO ADR OASMY

Healthcare Biotechnology Drug Manufacturers - Specialty & Generic
Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics,... see more

Recent & Breaking News (GREY:OASMY)

SHAREHOLDER ALERT - Oasmia Pharmaceutical AB (OASM) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: September 27, 2019

PR Newswire August 1, 2019

INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Oasmia Pharmaceutical AB and Encourages Investors with Losses to Contact the Firm

Press Releases July 31, 2019

Rosen, a Leading Law Firm, Files First Securities Class Action Lawsuit Against Oasmia Pharmaceutical AB; Encourages Investors with Losses in Excess of $100K to Contact the Firm - OASM

GlobeNewswire July 31, 2019

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Oasmia Pharmaceutical AB To Contact The Firm

PR Newswire July 31, 2019

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Oasmia Pharmaceutical AB (OASM)

GlobeNewswire July 31, 2019

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Oasmia Pharmaceutical AB and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

GlobeNewswire July 31, 2019

Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Oasmia Pharmaceutical AB Investors

Business Wire July 30, 2019

SHAREHOLDER DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Oasmia Pharmaceutical AB and Encourages Investors with Losses to Contact the Firm

Press Releases July 30, 2019

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Oasmia Pharmaceutical AB Investors (OASM)

Business Wire July 30, 2019

ROSEN, A TOP RANKED LAW FIRM, Files First Securities Class Action Lawsuit Against Oasmia Pharmaceutical AB; Encourages Investors with Losses in Excess of $100K to Contact the Firm - OASM

Business Wire July 30, 2019

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Oasmia Pharmaceutical AB and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Business Wire July 30, 2019

SHAREHOLDER ALERT - Oasmia Pharmaceutical AB (OASM) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Plaintiff Deadline: September 27, 2019

Press Releases July 30, 2019

Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Oasmia Pharmaceutical AB (NASDAQ: OASM) and Encourages Oasmia Investors to Contact the Firm

GlobeNewswire July 29, 2019

OASM CLASS ACTION ALERT: Hagens Berman Alerts Investors in Oasmia Pharmaceutical AB (OASM) to Securities Fraud Class Action

GlobeNewswire July 29, 2019

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Oasmia Pharmaceutical AB - OASM

PR Newswire July 29, 2019

Lifshitz & Miller LLP Announces Investigation of Caesars Entertainment Corporation, Del Frisco's Restaurant Group, Inc., Diebold Nixdorf, Inc., FedEx Corporation, Oasmia Pharmaceuticals, Shore Community Bancorp, Verb Technology Company and WageWorks, Inc.

PR Newswire July 26, 2019

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Oasmia Pharmaceutical AB and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

GlobeNewswire July 24, 2019

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Oasmia Pharmaceutical AB and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

GlobeNewswire July 19, 2019

EQUITY ALERT: Rosen Law Firm Continues to Investigate Securities Claims Against Oasmia Pharmaceutical AB - OASM

GlobeNewswire July 19, 2019

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Oasmia Pharmaceutical AB and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Business Wire July 18, 2019